Restore Medical

Company Overview

Snapshot

Founded in February 2015 by Elchanan Bruckheimer and Stephen Bellomo, Restore Medical operates with 11–50 employees. The company has raised $29.43 million across 5 funding rounds from 3 investors. In July 2024, Restore Medical received Breakthrough Device Designation from the FDA for its ContraBand™ System.

Business overview

Restore Medical is a Health Tech & Life Sciences company focused on improving the treatment of congestive heart failure (CHF). The company develops innovative medical devices, specifically the ContraBand system, which is the first and only transcatheter Pulmonary Artery Banding (PAB) system for patients with Heart Failure with reduced Ejection Fraction (HFrEF). This catheter-delivered implant is designed to leverage the right ventricle to support the left ventricle, aiming to improve ejection fraction and restore optimal ventricular geometry. Restore Medical's technology serves the cardiology and medical device markets, addressing a critical need for effective treatments for LV failure.

Strategic signal

In July 2024, Restore Medical's ContraBand™ System received Breakthrough Device Designation from the FDA. This designation is a significant validation of the technology's potential to address an unmet medical need for HFrEF patients, signaling to investors and the industry a faster path to market and potential for accelerated adoption due to its innovative approach to heart failure treatment.

Company Intelligence Q&A

What is the primary focus of Restore Medical?

Restore Medical is dedicated to improving the treatment of congestive heart failure (CHF) by developing innovative medical devices, specifically the ContraBand system, a transcatheter Pulmonary Artery Banding system.

When did Restore Medical receive Breakthrough Device Designation from the FDA?

Restore Medical received Breakthrough Device Designation from the FDA for its ContraBand™ System to treat HFrEF patients in July 2024.

What was the outcome of the first-in-human preliminary results for the ContraBand™ System?

In March 2023, Restore Medical announced successful first-in-human preliminary results for its ContraBand™ System for symptomatic systolic heart failure patients.

Who was appointed as Chairman of the Board in November 2025?

In November 2025, Restore Medical appointed Chris Cleary, a former Medtronic executive, as Chairman of the Board.